Oswald, Laura B.
Lyleroehr, Madison
Gudenkauf, Lisa M.
Armstrong, Grace E.
Tometich, Danielle B.
Sanford, Stacy D.
Loecher, Nele
Geiss, Carley
Rodriguez, Yvelise
Scheel, Kelsey L.
Nieves-Lopez, Amarilis
Jim, Heather S. L.
Gonzalez, Brian D.
Antoni, Michael H.
Penedo, Frank J.
Reed, Damon
Katsanis, Emmanuel
Salsman, John M.
Victorson, David
Fox, Rina S.
Funding for this research was provided by:
American Cancer Society Institutional Research Grant (IRG-174-173-22, IRG-18-163-24)
National Cancer Institute (R01CA242849, K08CA247973)
Article History
Received: 13 July 2022
Accepted: 1 October 2022
First Online: 14 October 2022
Declarations
:
: Dr. Jim is a consultant for RedHill BioPharma, Janssen Scientific Affairs, and Merck and has grant funding from Kite Pharma. Dr. Gonzalez is a consultant for SureMed Compliance and KemPharm, and an advisory board member for Elly Health, Inc. Dr. Antoni is a consultant for Blue Note Therapeutics and Atlantis Healthcare. Dr. Penedo is a consultant for Blue Note Therapeutics. Dr. Reed is a consultant for Springworks and Eisai. All other authors have no relevant financial or non-financial interests to disclose.
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by Advarra Institutional Review Board (Pro00000971) and Northwestern University’s Institutional Review Board (STU00214055).
: Informed consent to participate was obtained from all individual participants included in this study.
: All participants consented to having de-identified and aggregate study data published.
: Dr. Jim is a consultant for RedHill BioPharma, Janssen Scientific Affairs, and Merck and has grant funding from Kite Pharma. Dr. Gonzalez is a consultant for SureMed Compliance and KemPharm, and an advisory board member for Elly Health, Inc. Dr. Antoni is a consultant for Blue Note Therapeutics and Atlantis Healthcare. Dr. Penedo is a consultant for Blue Note Therapeutics. Dr. Reed is a consultant for SpringWorks and Eisai. All other authors have no relevant financial or non-financial interests to disclose.